Shares of Amedisys, Inc. (NASDAQ:AMED – Get Free Report) have been assigned a consensus recommendation of “Hold” from the eight research firms that are presently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $100.80.
Several analysts recently issued reports on the company. StockNews.com raised Amedisys from a “hold” rating to a “buy” rating in a report on Saturday, May 4th. Raymond James reissued a “market perform” rating on shares of Amedisys in a report on Tuesday, March 26th. Cantor Fitzgerald reissued a “neutral” rating and issued a $101.00 price target on shares of Amedisys in a report on Thursday, April 25th. Finally, Royal Bank of Canada lifted their target price on Amedisys from $97.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 25th.
Read Our Latest Research Report on AMED
Institutional Trading of Amedisys
Amedisys Price Performance
Shares of AMED opened at $94.08 on Friday. The firm has a market cap of $3.07 billion, a price-to-earnings ratio of -147.00, a PEG ratio of 3.43 and a beta of 0.84. The stock has a 50 day moving average of $92.32 and a 200-day moving average of $93.33. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31. Amedisys has a 52 week low of $73.10 and a 52 week high of $96.44.
Amedisys (NASDAQ:AMED – Get Free Report) last issued its earnings results on Wednesday, April 24th. The health services provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. The company had revenue of $571.41 million during the quarter, compared to analyst estimates of $565.38 million. Amedisys had a positive return on equity of 12.85% and a negative net margin of 0.91%. The business’s revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.00 EPS. As a group, analysts forecast that Amedisys will post 4.57 EPS for the current year.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Stories
- Five stocks we like better than Amedisys
- What Are Growth Stocks and Investing in Them
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- What is the NASDAQ Stock Exchange?
- Generac Powers Ahead on the Electrification Mega-Trend
- Are Penny Stocks a Good Fit for Your Portfolio?
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.